Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis | Zendy

Ajay Singh | Zendy; Kevin Carroll | Zendy; John J.V. McMurray | Zendy; Scott D. Solomon | Zendy; Vivekanand Jha | Zendy; Kirsten L. Johansen | Zendy; Renato D. Lópes | Zendy; Iain C. Macdougall | Zendy; Gregorio T. Obrador | Zendy; Sushrut S. Waikar | Zendy; Christoph Wanner | Zendy; David C. Wheeler | Zendy; Andrzej Więcek | Zendy; Allison Blackorby | Zendy; Borut Čižman | Zendy; Alexander R. Cobitz | Zendy; Rich Davies | Zendy; Tara DiMino | Zendy; Lata Kler | Zendy; Amy M. Meadowcroft | Zendy; Lin Taft | Zendy; Vlado Perkovic | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis

Author(s) -

Ajay Singh,

Kevin Carroll,

John J.V. McMurray,

Scott D. Solomon,

Vivekanand Jha,

Kirsten L. Johansen,

Renato D. Lópes,

Iain C. Macdougall,

Gregorio T. Obrador,

Sushrut S. Waikar,

Christoph Wanner,

David C. Wheeler,

Andrzej Więcek,

Allison Blackorby,

Borut Čižman,

Alexander R. Cobitz,

Rich Davies,

Tara DiMino,

Lata Kler,

Amy M. Meadowcroft,

Lin Taft,

Vlado Perkovic

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2113380

Subject(s) - dialysis , anemia , medicine , intensive care medicine

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In patients with chronic kidney disease (CKD) who are not undergoing dialysis, the efficacy and safety of daprodustat, as compared with the conventional erythropoiesis-stimulating agent darbepoetin alfa, are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research